A study testing whether a study medicine, Sodium-glucose cotransporter 2 inhibitors (SGLT2i), can help people with diabetic kidney disease protect their kidneys.

Recruiting now. Registry record last updated March 2, 2026.

Who can join: Adults 18+, have diabetic kidney disease.
What you take: Sodium-glucose cotransporter 2 inhibitors (SGLT2i), given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 3 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Not ApplicableSponsor University of PennsylvaniaDrug Sodium-glucose cotransporter 2 inhibitors (SGLT2i)Class OtherSites 1 USEnrollment target 200

What this study is for

Primary condition: Diabetic Nephropathies. Also studied in: Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2.

Full scientific study title: Transformative Research in Diabetic Nephropathy 2.0.

Who can join

Age18 and upSexAny

Adults 18+, have diabetic kidney disease. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Age ≥18 years
eGFR ≥10 ml/min/1.73 m2 based on the 2021 race-free CKD-EPI equation13
Underwent a clinically indicated kidney biopsy, living donor biopsy, or nephrectomy (non-tumor adjacent tissue available).
Able and willing to provide informed consent for release of one pathology and clinical data abstraction.

Key exclusion criteria

Inability to provide informed consent.
Archived biopsy or surgical tissue unavailable for slide preparation.
Any local institutional policy that prohibits release of H\&E slides for research.

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Pennsylvania1 site

Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
Gaia Coppock, MD2673030158Gaia.Coppock@pennmedicine.upenn.edu

Follow this trial

We email you if NCT07444203 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: November 12, 2025. Expected completion: November 12, 2028. Last updated on ClinicalTrials.gov: March 2, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.